Cargando…

A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy

BACKGROUND: Neck pain, sensory disturbance and motor dysfunction in most patients suffered cervical spondylotic myelopathy (CSM). However, some conservative treatments are limited by their modest effectiveness. In the other hand, surgical treatment is necessary when symptoms are refractory to conser...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chongqing, Zhou, Xiaoning, Tong, Zhengyi, Ma, Junming, Ye, Jie, Xu, Jinhai, Mo, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437772/
https://www.ncbi.nlm.nih.gov/pubmed/32872078
http://dx.doi.org/10.1097/MD.0000000000021776
_version_ 1783572685022822400
author Xu, Chongqing
Zhou, Xiaoning
Tong, Zhengyi
Ma, Junming
Ye, Jie
Xu, Jinhai
Mo, Wen
author_facet Xu, Chongqing
Zhou, Xiaoning
Tong, Zhengyi
Ma, Junming
Ye, Jie
Xu, Jinhai
Mo, Wen
author_sort Xu, Chongqing
collection PubMed
description BACKGROUND: Neck pain, sensory disturbance and motor dysfunction in most patients suffered cervical spondylotic myelopathy (CSM). However, some conservative treatments are limited by their modest effectiveness. In the other hand, surgical treatment is necessary when symptoms are refractory to conservative treatments and neurological function of the patients has deteriorated. Many patients use complementary and alternative medicine, including traditional Chinese medicine, to address their symptoms. The purpose of the present study is to examine effectiveness and safety of Yiqi-Huayu-Tongsui (YQHYTS) granule, a compound traditional Chinese herbal medicine, on symptoms in patients with mild or moderate CSM. METHODS/DESIGN: A randomized, double blinded, placebo-controlled clinical trial to evaluate the efficacy and safety of YQHYTS granule is proposed. 72 patients in Longhua Hospital with the diagnosis of mild or moderate CSM will be randomly allocated into 2 groups, and treated with YQHYTS granule or placebo. The prescription of the trial drugs (YQHYTS granule/placebo) is 20 grams twice a day for 3 months. The primary outcome measurements include visual analog scale, Japanese Orthopedic Association, and Neck Disability Index score. The secondary outcome measurements are electromyogram and Pfirrmann classification. DISCUSSION: YQHYTS granule has been established and applied in Longhua Hospital for many years. As it has a potential benefit in treating mild or moderate CSM, we designed a double-blind, prospective, randomized controlled trial and would like to publish the results and conclusions later. If YQHYTS granule can alleviate neck pain, sensory disturbance, and even motor dysfunction without adverse effects, it may be a unique strategy for the treatment of mild or moderate CSM. TRIAL REGISTRATION: Chinese Clinical Trial Registry ID: ChiCTR1900028192. Registered 15 December 2019, Available at: http://www.chictr.org.cn/edit.aspx?pid=46913&htm=4
format Online
Article
Text
id pubmed-7437772
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-74377722020-09-02 A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy Xu, Chongqing Zhou, Xiaoning Tong, Zhengyi Ma, Junming Ye, Jie Xu, Jinhai Mo, Wen Medicine (Baltimore) 3700 BACKGROUND: Neck pain, sensory disturbance and motor dysfunction in most patients suffered cervical spondylotic myelopathy (CSM). However, some conservative treatments are limited by their modest effectiveness. In the other hand, surgical treatment is necessary when symptoms are refractory to conservative treatments and neurological function of the patients has deteriorated. Many patients use complementary and alternative medicine, including traditional Chinese medicine, to address their symptoms. The purpose of the present study is to examine effectiveness and safety of Yiqi-Huayu-Tongsui (YQHYTS) granule, a compound traditional Chinese herbal medicine, on symptoms in patients with mild or moderate CSM. METHODS/DESIGN: A randomized, double blinded, placebo-controlled clinical trial to evaluate the efficacy and safety of YQHYTS granule is proposed. 72 patients in Longhua Hospital with the diagnosis of mild or moderate CSM will be randomly allocated into 2 groups, and treated with YQHYTS granule or placebo. The prescription of the trial drugs (YQHYTS granule/placebo) is 20 grams twice a day for 3 months. The primary outcome measurements include visual analog scale, Japanese Orthopedic Association, and Neck Disability Index score. The secondary outcome measurements are electromyogram and Pfirrmann classification. DISCUSSION: YQHYTS granule has been established and applied in Longhua Hospital for many years. As it has a potential benefit in treating mild or moderate CSM, we designed a double-blind, prospective, randomized controlled trial and would like to publish the results and conclusions later. If YQHYTS granule can alleviate neck pain, sensory disturbance, and even motor dysfunction without adverse effects, it may be a unique strategy for the treatment of mild or moderate CSM. TRIAL REGISTRATION: Chinese Clinical Trial Registry ID: ChiCTR1900028192. Registered 15 December 2019, Available at: http://www.chictr.org.cn/edit.aspx?pid=46913&htm=4 Lippincott Williams & Wilkins 2020-08-14 /pmc/articles/PMC7437772/ /pubmed/32872078 http://dx.doi.org/10.1097/MD.0000000000021776 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 3700
Xu, Chongqing
Zhou, Xiaoning
Tong, Zhengyi
Ma, Junming
Ye, Jie
Xu, Jinhai
Mo, Wen
A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy
title A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy
title_full A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy
title_fullStr A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy
title_full_unstemmed A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy
title_short A randomized, double-blind, placebo-controlled trial for Yi-Qi Hua-Yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy
title_sort randomized, double-blind, placebo-controlled trial for yi-qi hua-yu tong-sui granule in the treatment of mild or moderate cervical spondylotic myelopathy
topic 3700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437772/
https://www.ncbi.nlm.nih.gov/pubmed/32872078
http://dx.doi.org/10.1097/MD.0000000000021776
work_keys_str_mv AT xuchongqing arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT zhouxiaoning arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT tongzhengyi arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT majunming arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT yejie arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT xujinhai arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT mowen arandomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT xuchongqing randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT zhouxiaoning randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT tongzhengyi randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT majunming randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT yejie randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT xujinhai randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy
AT mowen randomizeddoubleblindplacebocontrolledtrialforyiqihuayutongsuigranuleinthetreatmentofmildormoderatecervicalspondyloticmyelopathy